Immunotherapy shrinks tumors before surgery in skin cancer trial

NCT ID NCT04154943

Completed Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested whether giving an immunotherapy drug called cemiplimab before surgery could help shrink or eliminate skin cancer tumors. It involved 79 patients with a type of skin cancer called cutaneous squamous cell carcinoma that had not spread to other organs. The main goal was to see if the drug could completely clear the cancer from the removed tissue, potentially leading to less extensive surgery and better long-term outcomes.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Regeneron Study Site

Palo Alto, California, 94304, United States
Regeneron Study Site

Washington D.C., District of Columbia, 20037, United States
Regeneron Study Site

Miami, Florida, 33176, United States
Regeneron Study Site

Tampa, Florida, 33612, United States
Regeneron Study Site

Baltimore, Maryland, 21231, United States
Regeneron Study Site

Boston, Massachusetts, 02114, United States
Regeneron Study Site

Boston, Massachusetts, 02215, United States
Regeneron Study Site

Ann Arbor, Michigan, 48109, United States
Regeneron Study Site

Omaha, Nebraska, 68114, United States
Regeneron Study Site

New York, New York, 10065, United States
Regeneron Study Site

Charlotte, North Carolina, 28204, United States
Regeneron Study Site

Durham, North Carolina, 27710, United States
Regeneron Study Site

Cleveland, Ohio, 44195, United States
Regeneron Study Site

Dallas, Texas, 75390, United States
Regeneron Study Site

Houston, Texas, 77030, United States
Regeneron Study Site

St Leonards, New South Wales, 2065, Australia
Regeneron Study Site

Herston, Queensland, 4029, Australia
Regeneron Study Site

Melbourne, Victoria, 3000, Australia
Regeneron Study Site

Dresden, 01307, Germany
Regeneron Study Site

Essen, 45147, Germany
Regeneron Study Site

Kiel, 24105, Germany
Regeneron Study Site

Tübingen, 72076, Germany

Conditions

Explore the condition pages connected to this study.

CUTANEOUS SQUAMOUS CELL CARCINOMA